Amgen Inc. (AMGN) FY2024 YTD Q3 P&L / Income Statement
2024-01-01 to 2024-09-30
Revenue by Product and Service by Geography
2024-01-01 to 2024-09-30
Swipe to see the full flow
Chart details
Amgen Inc. (AMGN) FY2024 YTD Q3 P&L / Income Statement
Income statement for 2024-01-01 through 2024-09-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.
- Total revenues
- 24,338,000,000 US dollars
- Cost of sales
- 9,746,000,000 US dollars
- Gross profit (calculated)
- 14,592,000,000 US dollars
- Operating expenses (calculated)
- 9,645,000,000 US dollars
- Operating income
- 4,947,000,000 US dollars
- Other income (expense), net (calculated)
- negative 1,120,000,000 US dollars
- Income before income taxes
- 3,827,000,000 US dollars
- Provision for income taxes
- 364,000,000 US dollars
- Net income
- 3,463,000,000 US dollars
- Aranesp - UNITED STATES
- 296,000,000 US dollars
- Aranesp - Non-US
- 738,000,000 US dollars
- BLINCYTO - UNITED STATES
- 555,000,000 US dollars
- BLINCYTO - Non-US
- 280,000,000 US dollars
- EVENITY - UNITED STATES
- 806,000,000 US dollars
- EVENITY - Non-US
- 326,000,000 US dollars
- ENBREL - UNITED STATES
- 2,280,000,000 US dollars
- ENBREL - Non-US
- 21,000,000 US dollars
- KRYSTEXXA - UNITED STATES
- 839,000,000 US dollars
- KRYSTEXXA - Non-US
- 0 US dollars
- Kyprolis - UNITED STATES
- 712,000,000 US dollars
- Kyprolis - Non-US
- 419,000,000 US dollars
- Nplate - UNITED STATES
- 749,000,000 US dollars
- Nplate - Non-US
- 370,000,000 US dollars
- Otezla - UNITED STATES
- 1,185,000,000 US dollars
- Otezla - Non-US
- 317,000,000 US dollars
- Other products - UNITED STATES
- 2,858,000,000 US dollars
- Other products - Non-US
- 1,204,000,000 US dollars
- Prolia - UNITED STATES
- 2,110,000,000 US dollars
- Prolia - Non-US
- 1,099,000,000 US dollars
- Repatha - UNITED STATES
- 824,000,000 US dollars
- Repatha - Non-US
- 792,000,000 US dollars
- TEPEZZA - UNITED STATES
- 1,379,000,000 US dollars
- TEPEZZA - Non-US
- 12,000,000 US dollars
- TEZSPIRE - UNITED STATES
- 676,000,000 US dollars
- TEZSPIRE - Non-US
- 0 US dollars
- Vectibix - UNITED STATES
- 385,000,000 US dollars
- Vectibix - Non-US
- 414,000,000 US dollars
- XGEVA - UNITED STATES
- 1,138,000,000 US dollars
- XGEVA - Non-US
- 526,000,000 US dollars
- Product sales - UNITED STATES
- 16,792,000,000 US dollars
- Product sales - Non-US
- 6,518,000,000 US dollars
- Research and development
- 4,240,000,000 US dollars
- Selling, general and administrative
- 5,218,000,000 US dollars
- Other
- 187,000,000 US dollars
- Revenue before reconciliation (calculated)
- 46,620,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
- Components above reported revenue (calculated)
- negative 22,282,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.
Chart connections
- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Gross margin
60.0%
Gross profit / revenue
Operating margin
20.3%
Operating profit / revenue
Cash conversion
194.0%
Operating cash / net income, same period
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!